Does J7515 require prior authorization?

Yes, J7515 requires prior authorization (medium confidence). Conditional coverage; review criteria to confirm PA need.

What is the Medicare reimbursement rate for J7515?

Medicare facility rate: N/A. Non-facility rate: N/A. Work RVU: 0.00.

Backwork Sign up free

`J7515`, Cyclosporine, oral, 25 mg

HCPCS/CPT

Prior Authorization

Prior Auth Required

Conditional coverage; review criteria to confirm PA need (medium confidence)

Medicare Pricing

Work RVU

0.00

Facility

N/A

Non-Facility

N/A

Documentation Required

A Standard Written Order (SWO) must be communicated to the supplier before a claim is submitted, and for DMEPOS base items requiring WOPD the supplier must have a signed WOPD prior to delivery.
Suppliers must maintain proof of delivery (POD) documentation in their files and produce POD upon request by the Medicare contractor.

For refills of DMEPOS items and supplies, suppliers must contact the beneficiary and document an affirmative response prior to dispensing the refill, and this contact must occur no sooner than 30 calendar days prior to the expected end of the current supply.

Treating practitioners billing for drugs must be enrolled as DMEPOS suppliers with the National Supplier Clearinghouse and must be authorized by the state to dispense drugs; documentation of enrollment and state dispensing authority is required.

Key Coverage Criteria

Immunosuppressive drugs are covered when FDA-approved and the approved labeling includes an indication for preventing or treating rejection of a transplanted organ or tissue.
Immunosuppressive drugs are covered when FDA-approved and the labeling indicates use in conjunction with immunosuppressive drugs to prevent or treat transplant rejection.
Immunosuppressive drugs are covered when FDA-approved and the DME MAC, in processing a Medicare claim, determines the drug is reasonable and necessary to prevent or treat rejection or to be used in conjunction with such drugs.
Compounded formulations derived solely from FDA-approved immunosuppressive drugs are covered when administered orally or enterally.
Dosage, frequency, and route of administration must conform to generally accepted medical practice and be medically necessary to prevent or treat organ transplant rejection.
Drugs that meet the above criteria are covered irrespective of whether they can be self-administered, subject to other policy limitations.

7 Active Policies

BCBSLA-00802-1FF1F8E9A7, 00802 Verkazia (cyclosporine ophthalmic emulsion)

HEALTHNET_OR-HNOR-CYCLOSPORINE-CEQUA-RESTASIS-VERKAZIA-VEVYE-KLARITY-C-CP-24CB97E25D, Cyclosporine (Cequa, Restasis, Verkazia, Vevye, Klarity-C); CP.PMN.48

OSCAR-RESTASIS-CYCLOSPORINE-0-05-OPHTHALMIC-EMULSIO-7186E387B6, Restasis (cyclosporine 0.05% ophthalmic emulsion) (PG025, Ver. 8)

OSCAR-VERKAZIA-CYCLOSPORINE-OPHTHALMIC-EMULSION-0-1-8DD0B1E851, Verkazia (cyclosporine ophthalmic emulsion) 0.1% (PG236, Ver. 2)

L33824, Immunosuppressive Drugs

AETNA-CPB-0423, Alopecia Areata

AETNA-CPB-0355, Extracorporeal Immunoadsorption (Prosorba Column)

`J7515`, Cyclosporine, oral, 25 mg

Prior Authorization

Medicare Pricing

Documentation Required

Key Coverage Criteria

7 Active Policies

Related Codes

Have a follow-up question?

J7515, Cyclosporine, oral, 25 mg

Prior Authorization

Medicare Pricing

Documentation Required

Key Coverage Criteria

7 Active Policies

Related Codes

Have a follow-up question?

`J7515`, Cyclosporine, oral, 25 mg